全文获取类型
收费全文 | 532篇 |
免费 | 37篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 7篇 |
妇产科学 | 45篇 |
基础医学 | 82篇 |
口腔科学 | 8篇 |
临床医学 | 38篇 |
内科学 | 163篇 |
皮肤病学 | 4篇 |
神经病学 | 69篇 |
特种医学 | 12篇 |
外科学 | 30篇 |
综合类 | 2篇 |
预防医学 | 43篇 |
药学 | 37篇 |
中国医学 | 2篇 |
肿瘤学 | 44篇 |
出版年
2024年 | 2篇 |
2023年 | 14篇 |
2022年 | 18篇 |
2021年 | 28篇 |
2020年 | 26篇 |
2019年 | 17篇 |
2018年 | 30篇 |
2017年 | 8篇 |
2016年 | 15篇 |
2015年 | 25篇 |
2014年 | 33篇 |
2013年 | 27篇 |
2012年 | 44篇 |
2011年 | 53篇 |
2010年 | 24篇 |
2009年 | 22篇 |
2008年 | 33篇 |
2007年 | 39篇 |
2006年 | 25篇 |
2005年 | 18篇 |
2004年 | 27篇 |
2003年 | 19篇 |
2002年 | 14篇 |
2001年 | 7篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1985年 | 2篇 |
排序方式: 共有588条查询结果,搜索用时 15 毫秒
581.
Veronica Boero MD PhD Riccardo Cavalli MD Carlotta Caia MD Alfredo Berrettini MD Giulia Emily Cetera MD Ermelinda Monti MD Giussy Barbara MD Giorgia Carlotta Albertini MD Elisa Restelli MD Giada Libutti MD Tiziano Motta MD Caterina Lazzari MD Paolo Vercellini MD 《Pediatric dermatology》2023,40(3):472-475
Background and Objectives
Although data regarding the rates of remission and progression of the disease are still scarce, it is generally now acknowledged that pediatric vulvar lichen sclerosus (pVLS) can persist beyond puberty. Recent studies reveal that this condition may persist in as many as 75% of cases. The present study aims to answer the following query: how does pVLS evolve after menarche?Methods
This observational retrospective study conducted on premenarchal girls diagnosed with pVLS in our institution between 1990 and 2011 describes 31 patients who returned for multidisciplinary clinical evaluation following menarche.Results
The mean follow-up time was 14 years. At the post-menarche clinical examination, patients were classified as follows: 58% were still affected by VLS, 16% presented with a complete remission of disease, and 26% were completely asymptomatic although with persistent clinical signs of VLS.Conclusions
In our series, pVLS persists following menarche in the majority of patients. These findings suggest the importance of a long-term follow-up even among patients who report resolution of symptoms following menarche. 相似文献582.
Boheng Zhu Sara Gostoli Giada Benasi Chiara Patierno Maria Letizia Petroni Chiara Nuccitelli Giulio Marchesini Giovanni A. Fava Chiara Rafanelli 《Clinical psychology & psychotherapy》2023,30(2):422-435
Behavioural lifestyle interventions focused on diet and physical activity are a cornerstone for the treatment of obesity. However, their effects vary substantially across individuals in terms of magnitude and durability. Personalized approaches that target psychological well-being may be promising to facilitate healthy behaviours and sustained weight loss. This preliminary study aimed to explore whether the sequential combination of behavioural lifestyle intervention (BLI) and well-being therapy (WBT) may result in more favourable outcomes than BLI alone in promoting weight loss (primary outcome) and improving psychological well-being, distress, dietary behaviours and physical activity (secondary outcomes). A total of 83 patients with obesity were randomly assigned to BLI/WBT (N = 38) or BLI group (N = 45). The BLI group received a 12-week behavioural weight loss programme, whereas the BLI/WBT group received the same programme followed by an additional 4-week WBT, adapted for group interventions. Data were collected at pretreatment (baseline, T1), at the end of BLI/WBT (T2), at 6-month (T3) and 12-month (T4) follow-ups. There was a significant weight loss in both treatment groups at T2, T3 and T4. The BLI/WBT group showed greater improvements in depressive symptoms at T3 and T4, in autonomy at T2, in personal growth at T4 and in global well-being at T4 compared with BLI group. WBT yielded no additional effect on weight loss. However, the secondary outcomes indicate that WBT may have enduring effects that reduce vulnerability to psychological distress in patients with obesity. In order to confirm these preliminary findings and explore whether a more intensive and individualized WBT can foster sustained weight loss, future studies are needed. 相似文献
583.
Gemma Marinella Eugenia Conti Bianca Buchignani Giada Sgherri Rosa Pasquariello Flavio Giordano Paola Cristofani Roberta Battini Agatino Battaglia 《American journal of medical genetics. Part A》2023,191(2):540-545
Nuclear Factor I B (NFIB) haploinsufficiency has recently been identified as a cause of intellectual disability (ID) and macrocephaly. Here we report on two new individuals carrying a microdeletion in the chromosomal region 9p23-p22.3 containing NFIB. The first is a 7-year 9-month old boy with developmental delays, ID, definite facial anomalies, and brain and spinal cord magnetic resonance imaging findings including periventricular nodular heterotopia, hypoplasia of the corpus callosum, arachnoid cyst in the left middle cranial fossa, syringomyelia in the thoracic spinal cord and distal tract of the conus medullaris, and a stretched appearance of the filum terminale. The second is a 32-year-old lady (the proband' mother) with dysmorphic features, and a history of learning disability, hypothyroidism, poor growth, left inguinal hernia, and panic attacks. Her brain magnetic resonance imaging findings include a dysmorphic corpus callosum, and a small cyst in the left choroidal fissure that marks the hippocampal head. Array-based comparative genomic hybridization identified, in both, a 232 Kb interstitial deletion at 9p23p22.3 including several exons of NFIB and no other known genes. Our two individuals add to the knowledge of this rare disorder through the addition of new brain and spinal cord MRI findings and dysmorphic features. We propose that NFIB haploinsufficiency causes a clinically recognizable malformation-ID syndrome. 相似文献
584.
585.
586.
Charlotte H. Markey Esben Strodl Annie Aimé Marita McCabe Rachel Rodgers Alvaro Sicilia Gianluca Lo Coco Jacinthe Dion David Mellor Giada Pietrabissa Salvatore Gullo Antonio Granero-Gallegos Michel Probst Christophe Maïano Catherine Bégin Manuel Alcaraz-Ibáñez Marie-Eve Blackburn Marie L. Caltabiano Gian Mauro Manzoni Gianluca Castelnuovo Naomi Hayami-Chisuwa Qiqiang He Matthew Fuller-Tyszkiewicz 《British journal of health psychology》2023,28(1):136-155
587.
Amine Benmassaoud Juan Macias Adèle Delamarre Anaïs Corma-Gomez Giovanni Guaraldi Jovana Milic Jürgen K. Rockstroh Kathrin Van Bremen Emmanuel Tsochatzis Akhilesh Mulay Jennifer Price Lucy J. Garvey Maud Lemoine Dana Kablawi Bertrand Lebouche Marina B. Klein Luz R. Ballesteros Christopher Boesecke Filippo Schepis Sanjay Bhagani Graham Cooke Annalisa Berzigotti Kyoko Hirose Juan A. Pineda Agnihotram V. Ramanakumar Victor De-Ledinghen Sahar Saeed Giada Sebastiani 《Liver international》2023,43(7):1427-1439
Background and Aims
People living with HIV (PLWH) are at high risk for advanced chronic liver disease and related adverse outcomes. We aimed to validate the prognostic value of non-invasive scores based on liver stiffness measurement (LSM) and on markers of portal hypertension (PH), namely platelets and spleen diameter, in PLWH.Methods
We combined data from eight international cohorts of PLWH with available non-invasive scores, including LSM and the composite biomarkers liver stiffness-spleen size-to-platelet ratio score (LSPS), LSM-to-Platelet ratio (LPR) and PH risk score. Incidence and predictors of all-cause mortality, any liver-related event and classical hepatic decompensation were determined by survival analysis, controlling for competing risks for the latter two. Non-invasive scores were assessed and compared using area under the receiver operating curve (AUROC).Results
We included 1695 PLWH (66.8% coinfected with hepatitis C virus). During a median follow-up of 4.7 (interquartile range 2.8–7.7) years, the incidence rates of any liver-related event, all-cause mortality and hepatic decompensation were 13.7 per 1000 persons-year (PY) (95% confidence interval [CI], 11.4–16.3), 13.8 per 1000 PY (95% CI, 11.6–16.4) and 9.9 per 1000 PY (95% CI, 8.1–12.2), respectively. The AUROC of LSM was similar to that of the composite biomarkers, ranging between 0.83 and 0.86 for any liver-related event, 0.79–0.85 for all-cause mortality and 0.87–0.88 for classical hepatic decompensation. All individual non-invasive scores remained independent predictors of clinical outcomes in multivariable analysis.Conclusions
Non-invasive scores based on LSM, spleen diameter and platelets predict clinical outcomes in PLWH. Composite biomarkers do not achieve higher prognostic performance compared to LSM alone. 相似文献588.
Anna Elisabetta Vaudano Alice Ballerini Francesca Zucchini Elisa Micalizzi Simona Scolastico Francesca Talami Giada Giovannini Matteo Pugnaghi Niccolò Orlandi Niccolò Biagioli Maria Cristina Cioclu Stefano Vallone Maurilio Genovese Alessandra Todeschini Francesca Cavalleri Marcella Malagoli Stefano Meletti 《Epileptic Disord》2023,25(1):45-56